The Power of CAR-Ms
With Dr. Minna Roh-Johnson
![Dr. Minna Roh-Johnson](/uploads/rohjohnson_image_bio_headshot_hero_web_bf5bc393a3.png)
![](/scroll_indicator.gif)
Micromanaging macrophages.
From the lab of Dr. Minna Roh-Johnson
The development of chimeric antigen receptor macrophages (CAR-Ms) to create a proper anti-tumor macrophage phenotype opens possibilities for therapeutic cancer interventions.
The premise is that macrophages can readily infiltrate solid tumors. If a macrophage can be “taught” to engulf a specific cancer cell, it could be introduced to the cancer environment as a powerful therapeutic.
Dr. Mina Roh-Johnson’s lab has developed CAR-Ms in vitro and they have proven effective at killing melanoma cells. Now her team is looking at the regulation and function of these CAR-Ms in vivo, and testing whether they can communicate to endogenous macrophages to elicit a robust anti-tumor response.
![](/uploads/02_skin_rohjohnson_image_breakthrough_web_48b9f168dd.jpg)
“The best results are when you see something you didn't expect under the microscope.”
Dr. Minna Roh-Johnson leads the University of Utah’s biochemistry lab. The primary focus of her research is cell biology and unlocking the mysteries of cell migration, particularly in cancer cells.
![Dr. Minna Roh-Johnson](/uploads/rohjohnson_image_bio_headshot_hero_web_bf5bc393a3.png)
Experience more breakthroughs and download Dr. Minna Roh-Johnson ’s full research report.
![Experience more breakthroughs and download Dr. Minna Roh-Johnson ’s full research report.](/uploads/02_skin_rohjohnson_image_vignette_breakthrough_download_hero_web_89f728ce53.png)
Connect with us to go deeper on this research and receive updates on future breakthroughs.
Join us live
Locate a ZEISS event near you and discover the power of possibilities.
![](/uploads/events_image_web_6afc7cfd70.jpg)